Polymyxin B-conjugated alpha 2-macroglobulin as an adjunctive therapy to sepsis: Modes of action and impact on lethality.
A drug targeting both the inflammatory initiators (lipopolysaccharide; LPS) and mediators [tumor necrosis factor-alpha (TNF-alpha)] should have advantage over a "single-factor targeting strategy" in sepsis prevention trials. We have prepared conjugates of polymyxin B (PMB) and the cytokine binding protein alpha2-macroglobulin (A2M). The conjugate binds TNF-alpha as well as LPS as studied by electrophoresis and phase partitioning. Compared with free PMB, the conjugate is nontoxic to cells and does not affect the viability of human monocytes. The A2M-PMB conjugate binds to the A2M receptor (CD91/low-density lipoprotein receptor-related protein 1) with affinity similar to that of the nonmodified protein. Fluorescein isothiocyanate-labeled LPS in the presence of A2M-PMB is rapidly transported into fibroblasts for degradation via receptor-mediated endocytosis. In vitro, A2M-PMB demonstrated inhibition of LPS-induced secretion of TNF-alpha from isolated monocytes as well as in the whole blood assay. The efficacy of the drug was tested in mice after induction of acute inflammation (LPS model) and after induction of a polymicrobial sepsis by cecal ligation and puncture (CLP) model. Treatment of mice with A2M-PMB up to 250 microg/g body weight was not toxic to the animal. When the drug was administered 30 min before or 30 min after the LPS challenge, a survival rate of 90 and 70%, respectively, was obtained compared with the placebo control group (5%). A2M-PMB also protected mice after induction of polymicrobial sepsis when administered 30 min before CLP. These results support our hypothesis that A2M-PMB acts as a polyvalent drug to target different host mediators as well as sepsis inducer at the same time.
Birkenmeier
Gerd
G
Institute of Biochemistry, University of Leipzig, Leipzig, Germany. birg@medizin.unileipzig.de
Nicklisch
Silke
S
Pockelt
Christiane
C
Mossie
Andualem
A
Steger
Volker
V
Gläser
Christiane
C
Hauschildt
Sunna
S
Usbeck
Elke
E
Huse
Klaus
K
Sack
Ulli
U
Bauer
Michael
M
Schäfer
Angelika
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use* / Q000633:toxicity; D001424:Bacterial Infections / Q000401:mortality / Q000517:prevention & control; D015153:Blotting, Western; D002469:Cell Separation; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D003911:Dextrans / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D008033:Limulus Test; D008070:Lipopolysaccharides; D051379:Mice; D008807:Mice, Inbred BALB C; D011112:Polymyxin B / Q000627:therapeutic use* / Q000633:toxicity; D018121:Receptors, Cytokine / Q000378:metabolism; D011955:Receptors, Drug / Q000378:metabolism; D018805:Sepsis / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000627:therapeutic use* / Q000633:toxicity
D000900:Anti-Bacterial Agents; D016207:Cytokines; D003911:Dextrans; D008070:Lipopolysaccharides; D018121:Receptors, Cytokine; D011955:Receptors, Drug; D014409:Tumor Necrosis Factor-alpha; D000511:alpha-Macroglobulins; D011112:Polymyxin B